{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:03:04Z","timestamp":1792000984677,"version":"4.4.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,27]],"date-time":"2017-06-27T00:00:00Z","timestamp":1498521600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","semarthritisrheumatism.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.semarthrit.2017.06.006","type":"journal-article","created":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T09:46:35Z","timestamp":1498211195000},"page":"295-302","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":83,"title":["Adult onset Still\u2019s disease\u2014The evidence that anti-interleukin-1 treatment is effective and well-tolerated (a comprehensive literature review)"],"prefix":"10.1016","volume":"47","author":[{"given":"Guido","family":"Junge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"June","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugen","family":"Feist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2017.06.006_bib1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1136\/ard.30.2.121","article-title":"Still\u2019s disease in the adult","volume":"30","author":"Bywaters","year":"1971","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.06.006_bib2","first-page":"2345","article-title":"Interleukin 1 inhibition with anakinra in adult-onset Still disease: a meta-analysis of its efficacy and safety","volume":"8","author":"Hong","year":"2014","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.semarthrit.2017.06.006_bib3","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/01.rhu.0000089966.48691.7f","article-title":"Successful treatment of a patient with refractory adult-onset Still disease with anakinra","volume":"9","author":"Rudinskaya","year":"2003","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.06.006_bib4","first-page":"293","article-title":"Anakinra in the treatment of adult-onset Still\u2019s disease","volume":"63","author":"Haraoui","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.06.006_bib5","first-page":"293","article-title":"Prompt response to treatment with anakinra in Adult Onset Still\u2019s Disease","volume":"63","author":"Aelion","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.06.006_bib6","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1136\/ard.2004.026617","article-title":"Refractory adult onset Still\u2019s disease successfully treated with anakinra","volume":"64","author":"Godinho","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.06.006_bib7","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/RHU.0b013e318188b8d8","article-title":"Efficacy of anakinra in a case of refractory Still disease","volume":"14","author":"Debiais","year":"2008","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.06.006_bib8","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s10067-007-0791-y","article-title":"Acute hepatitis in adult Still\u2019s disease during corticosteroid treatment successfully treated with anakinra","volume":"27","author":"Mylona","year":"2008","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.06.006_bib9","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1002\/art.24826","article-title":"Thrombotic microangiopathy and Purtscher-like retinopathy associated with adult-onset Still\u2019s disease: a role for glomerular vascular endothelial growth factor?","volume":"61","author":"El Karoui","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2017.06.006_bib10","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1468-3083.2008.2746.x","article-title":"Adult-onset Still\u2019s disease: an uncommon differential diagnosis of urticaria and treatment with anakinra","volume":"23","author":"Gesierich","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.semarthrit.2017.06.006_bib11","first-page":"733","article-title":"Treatment challenges in patient with refractory adult Still\u2019s disease\u2014a case report","volume":"27","author":"Sentic","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.06.006_bib12","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1007\/s10067-010-1459-6","article-title":"May anakinra be used earlier in adult onset Still disease?","volume":"29","author":"Moulis","year":"2010","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.06.006_bib13","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1111\/j.1756-185X.2010.01474.x","article-title":"A case of refractory adult-onset Still\u2019s disease treated with anakinra","volume":"13","author":"Lahiri","year":"2010","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.06.006_bib14","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3109\/s10165-009-0254-1","article-title":"Marked effect and steroid-sparing ability of anakinra on a patient with refractory adult-onset Still\u2019s disease","volume":"20","author":"Tamaki","year":"2010","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.06.006_bib15","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jbspin.2010.09.014","article-title":"Adult-onset Still\u2019s disease with myocarditis successfully treated with the interleukin-1 receptor antagonist anakinra","volume":"78","author":"Raffeiner","year":"2011","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.semarthrit.2017.06.006_bib16","first-page":"2","article-title":"Successful treatment of refractory adult onset Still\u2019s disease with anakinra","volume":"41","author":"Brusch","year":"2011","journal-title":"Intern Med J"},{"key":"10.1016\/j.semarthrit.2017.06.006_bib17","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jbspin.2013.04.011","article-title":"Reactive macrophage activation syndrome possibly triggered by canakinumab in a patient with adult-onset Still\u2019s disease","volume":"80","author":"Banse","year":"2013","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.semarthrit.2017.06.006_bib18","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.semarthrit.2013.09.003","article-title":"A case of bilateral trochleitis in adult-onset Still\u05f3s disease","volume":"43","author":"Gutmark","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2017.06.006_bib19","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ijcard.2015.04.071","article-title":"Myocarditis in a young man with adult onset Still\u2019s disease successfully treated with Il-1 blocker","volume":"189","author":"Luconi","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.semarthrit.2017.06.006_bib20","first-page":"130","article-title":"A severe case of adult onset Stills disease with myopericarditis, resistant to treatment with tocilizumab but responsive to anakinra","volume":"84","author":"Waghmare","year":"2015","journal-title":"Ulster Med J"},{"key":"10.1016\/j.semarthrit.2017.06.006_bib21","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/art.21061","article-title":"Rapid responses to anakinra in patients with refractory adult-onset Still\u2019s disease","volume":"52","author":"Fitzgerald","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2017.06.006_bib22","first-page":"4101","article-title":"Interleukin-1 blockade is an effective treatment of adult onset Still\u2019s disease","volume":"52","author":"Chu","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2017.06.006_bib23","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1136\/ard.2006.066381","article-title":"Anakinra treatment in patients with adult-onset Still\u2019s disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial","volume":"66","author":"Kalliolias","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.06.006_bib24","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.semarthrit.2007.04.002","article-title":"Anakinra in patients with treatment-resistant adult-onset Still\u2019s disease: four case reports with serial cytokine measurements and a review of the literature","volume":"37","author":"K\u00f6tter","year":"2007","journal-title":"Semin Arthritis Rheu"},{"key":"10.1016\/j.semarthrit.2017.06.006_bib25","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1136\/ard.2009.108068","article-title":"IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still\u2019s disease","volume":"69","author":"Naumann","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.06.006_bib26","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1002\/art.27532","article-title":"Efficacy of traditional and biologic agents in different clinical phenotypes of adult-onset Still\u2019s disease","volume":"62","author":"Franchini","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2017.06.006_bib27","doi-asserted-by":"crossref","first-page":"R91","DOI":"10.1186\/ar3366","article-title":"Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still\u2019s disease: a case-series study","volume":"13","author":"Laskari","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2017.06.006_bib28","doi-asserted-by":"crossref","first-page":"349521","DOI":"10.1155\/2012\/349521","article-title":"Adult-onset Still\u2019s disease masquerading as sepsis in an asplenic active duty soldier","volume":"2012","author":"Jaqua","year":"2012","journal-title":"Case Rep Med"},{"issue":"Suppl. 10","key":"10.1016\/j.semarthrit.2017.06.006_bib29","first-page":"2028","article-title":"Efficacy and safety of biologic agents in adult-onset Still\u2019s disease: a long-term follow-up of 19 patients at a single referral center","volume":"65","author":"Cavalli","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2017.06.006_bib30","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3109\/03009742.2014.992949","article-title":"Efficacy and safety of biological agents in adult-onset Still\u2019s disease","volume":"44","author":"Cavalli","year":"2015","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.06.006_bib31","first-page":"47","article-title":"Adult-onset Still\u2019s disease: clinical, serological and therapeutic considerations","volume":"31","author":"Iliou","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.06.006_bib32","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.autrev.2014.08.032","article-title":"Adult onset Still\u2019s disease (AOSD) in the era of biologic therapies: dichotomous view for cytokine and clinical expressions","volume":"13","author":"Maria","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2017.06.006_bib33","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/MD.0000000000000021","article-title":"Adult-onset still disease manifestations, treatment, outcome, and prognostic factors in 57 patients","volume":"93","author":"Gerfaud-Valentin","year":"2014","journal-title":"Medicine"},{"key":"10.1016\/j.semarthrit.2017.06.006_bib34","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.3899\/jrheum.111549","article-title":"Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still\u2019s disease. An open, randomized, multicenter study","volume":"39","author":"Nordstrom","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.06.006_bib35","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1136\/ard.2007.076034","article-title":"Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France","volume":"67","author":"Lequerre","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.06.006_bib36","first-page":"S373","article-title":"Long term treatment with anakinra in patients with adult-onset Still\u2019s disease","volume":"10","author":"Giampietro","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2017.06.006_bib37","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/acr.21901","article-title":"Anakinra in adult-onset Still\u2019s disease: long-term treatment in patients resistant to conventional therapy","volume":"65","author":"Giampietro","year":"2013","journal-title":"Arthrit Care Res"},{"key":"10.1016\/j.semarthrit.2017.06.006_bib38","first-page":"10","article-title":"Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey","author":"Rossi-Semerano","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.semarthrit.2017.06.006_bib39","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000001554","article-title":"Efficacy of anakinra in refractory adult-onset Still\u2019s disease multicenter study of 41 patients and literature review","volume":"94","author":"Ortiz-Sanjuan","year":"2015","journal-title":"Medicine"},{"key":"10.1016\/j.semarthrit.2017.06.006_bib40","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.semarthrit.2012.03.004","article-title":"The use of canakinumab, a novel IL-1 beta long-acting inhibitor, in refractory adult-onset Still\u2019s disease","volume":"42","author":"Kontzias","year":"2012","journal-title":"Semin Arthritis Rheu"},{"key":"10.1016\/j.semarthrit.2017.06.006_bib41","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/RHU.0000000000000082","article-title":"Successful treatment of refractory adult-onset still disease with canakinumab: a case report","volume":"20","author":"Barsotti","year":"2014","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.06.006_bib42","first-page":"262","article-title":"Differential response to the long acting IL-1 inhibitor IL-1 trap in 2 patients with Adult Onset Still\u2019s Disease (AOSD)","volume":"65","author":"Goldbach-Mansky","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.06.006_bib43","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1136\/annrheumdis-2012-201409","article-title":"IL-1 trap rilonacept in refractory adult onset Still\u2019s disease","volume":"71","author":"Petryna","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.06.006_bib44","first-page":"1831","article-title":"Safety and efficacy of IL-1 trap in resistant adult onset Still\u2019s disease: 24 month follow-up of open label treatment and biomarkers of response","volume":"62","author":"Henderson","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2017.06.006_bib45","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.3899\/jrheum.130325","article-title":"A patient with a phenotype of adult-onset still disease, but a genotype typical of cryopyrin-associated periodic fever syndrome","volume":"40","author":"Eriksson","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.06.006_bib46","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.jbspin.2013.12.011","article-title":"Canakinumab in a case of adult onset Still\u2019s disease: efficacy only on systemic manifestations","volume":"81","author":"Lo Gullo","year":"2014","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.semarthrit.2017.06.006_bib47","first-page":"S424","article-title":"Adult Still\u2019s disease: successful treatment with canakinumab","volume":"25","author":"Athanassiou","year":"2014","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.semarthrit.2017.06.006_bib48","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s10067-005-0138-5","article-title":"A multicenter study of patients with adult-onset Still\u2019s disease compared with systemic juvenile idiopathic arthritis","volume":"25","author":"Pay","year":"2006","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.06.006_bib49","first-page":"373","article-title":"Corticosteroid sparing effect of low dose methotrexate treatment in adult Still\u2019s disease","volume":"26","author":"Fautrel","year":"1999","journal-title":"J Rheumatol"},{"issue":"Suppl. 2","key":"10.1016\/j.semarthrit.2017.06.006_bib50","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1136\/annrheumdis-2014-eular.2320","article-title":"OP0007 Changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy","volume":"73","author":"Brachat","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.06.006_bib51","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12969-015-0047-3","article-title":"Gene-expression analysis of adult-onset Still\u2019s disease and systemic juvenile idiopathic arthritis is consistent with a continuum of a single disease entity","volume":"13","author":"Nirmala","year":"2015","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.semarthrit.2017.06.006_bib52","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.berh.2016.08.003","article-title":"Adult-onset Still\u2019s disease: advances in the treatment","volume":"30","author":"Casta\u00f1eda","year":"2016","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.06.006_bib53","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1002\/art.38398","article-title":"Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still\u2019s disease: multicenter retrospective open-label study of thirty-four patients","volume":"66","author":"Ortiz-Sanju\u00e1n","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.06.006_bib54","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.berh.2012.07.002","article-title":"Biological treatment in adult-onset Still\u2019s disease","volume":"26","author":"Pouchot","year":"2012","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.06.006_bib55","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/art.30128","article-title":"Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series","volume":"63","author":"Nigrovic","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2017.06.006_bib56","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/art.38296","article-title":"Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study","volume":"66","author":"Vastert","year":"2014","journal-title":"Arthritis Rheumatol"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017216304991?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017216304991?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T23:36:44Z","timestamp":1750376204000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017216304991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S0049017216304991"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2017.06.006","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adult onset Still\u2019s disease\u2014The evidence that anti-interleukin-1 treatment is effective and well-tolerated (a comprehensive literature review)","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2017.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}